An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature

Alopecia areata is a common autoimmune disease, with a negative impact in health-related quality of life, especially when affecting children and adolescents. Current medical therapies, mainly for severe disease, are not effective. There are no FDA (Food and Drug Administration)- or ANVISA (Agencia Nacional de Vigilancia Sanitaria)-approved therapy for children with alopecia areata. JAK inhibitors are emerging as a promising therapy.